Cargando…
Immunization Against Group B Streptococci vs. Intrapartum Antibiotic Prophylaxis in Peripartum Pregnant Women and their Neonates: A Review
Group B streptococcus (GBS) is an organism that has an immense global impact on neonatal morbidity and mortality. GBS is known to colonize the gastrointestinal and genitourinary tracts of infected pregnant women. Transmission to the neonate is achieved during labor and delivery. Complications of neo...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017184/ https://www.ncbi.nlm.nih.gov/pubmed/29946507 http://dx.doi.org/10.7759/cureus.1775 |
_version_ | 1783334693746245632 |
---|---|
author | Kristeva, Mariya Tillman, Catherine Goordeen, Ashley |
author_facet | Kristeva, Mariya Tillman, Catherine Goordeen, Ashley |
author_sort | Kristeva, Mariya |
collection | PubMed |
description | Group B streptococcus (GBS) is an organism that has an immense global impact on neonatal morbidity and mortality. GBS is known to colonize the gastrointestinal and genitourinary tracts of infected pregnant women. Transmission to the neonate is achieved during labor and delivery. Complications of neonatal infection include sepsis, meningitis, and pneumonia. Preventative measures are needed to reduce the disease burden. The current method of prophylaxis being utilized is intrapartum antibiotics. Though effective, it presents limitations that include a required, lengthy duration of treatment, increased antibiotic resistance, and lack of late-onset disease coverage. Recent studies are exploring alternative methods of prophylaxis such as vaccination. Vaccination provides coverage of both early and late-onset disease to infected women who are unable to complete the required four hours of antibiotic course intrapartum, women with resistance to antibiotic infections, and women delivering in resource-poor areas without access to antibiotics. An investigational CRM197 conjugated trivalent vaccine has shown a good immunogenicity profile against the three most prevalent serotypes. The vaccine induced antibodies freely cross the placenta and persist in a neonate for up to 90 days after birth. Additionally, the vaccine possesses a safety profile free of any serious systemic adverse effects and only mild pain at the injection site. Future studies should focus on investigating the effect of the vaccine on maternal rectovaginal acquisition and subsequent vaginal colonization, as well as the expansion of vaccine coverage to all 10 serotypes identified worldwide in order to facilitate its use in resource-poor areas of the world with inadequate antibiotic availability. If available, such a vaccine can serve as an effective supplement to current guidelines of antibiotic prophylaxis against GBS in peripartum women and their neonates. |
format | Online Article Text |
id | pubmed-6017184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-60171842018-06-26 Immunization Against Group B Streptococci vs. Intrapartum Antibiotic Prophylaxis in Peripartum Pregnant Women and their Neonates: A Review Kristeva, Mariya Tillman, Catherine Goordeen, Ashley Cureus Obstetrics/Gynecology Group B streptococcus (GBS) is an organism that has an immense global impact on neonatal morbidity and mortality. GBS is known to colonize the gastrointestinal and genitourinary tracts of infected pregnant women. Transmission to the neonate is achieved during labor and delivery. Complications of neonatal infection include sepsis, meningitis, and pneumonia. Preventative measures are needed to reduce the disease burden. The current method of prophylaxis being utilized is intrapartum antibiotics. Though effective, it presents limitations that include a required, lengthy duration of treatment, increased antibiotic resistance, and lack of late-onset disease coverage. Recent studies are exploring alternative methods of prophylaxis such as vaccination. Vaccination provides coverage of both early and late-onset disease to infected women who are unable to complete the required four hours of antibiotic course intrapartum, women with resistance to antibiotic infections, and women delivering in resource-poor areas without access to antibiotics. An investigational CRM197 conjugated trivalent vaccine has shown a good immunogenicity profile against the three most prevalent serotypes. The vaccine induced antibodies freely cross the placenta and persist in a neonate for up to 90 days after birth. Additionally, the vaccine possesses a safety profile free of any serious systemic adverse effects and only mild pain at the injection site. Future studies should focus on investigating the effect of the vaccine on maternal rectovaginal acquisition and subsequent vaginal colonization, as well as the expansion of vaccine coverage to all 10 serotypes identified worldwide in order to facilitate its use in resource-poor areas of the world with inadequate antibiotic availability. If available, such a vaccine can serve as an effective supplement to current guidelines of antibiotic prophylaxis against GBS in peripartum women and their neonates. Cureus 2017-10-13 /pmc/articles/PMC6017184/ /pubmed/29946507 http://dx.doi.org/10.7759/cureus.1775 Text en Copyright © 2017, Kristeva et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Obstetrics/Gynecology Kristeva, Mariya Tillman, Catherine Goordeen, Ashley Immunization Against Group B Streptococci vs. Intrapartum Antibiotic Prophylaxis in Peripartum Pregnant Women and their Neonates: A Review |
title | Immunization Against Group B Streptococci vs. Intrapartum Antibiotic Prophylaxis in Peripartum Pregnant Women and their Neonates: A Review |
title_full | Immunization Against Group B Streptococci vs. Intrapartum Antibiotic Prophylaxis in Peripartum Pregnant Women and their Neonates: A Review |
title_fullStr | Immunization Against Group B Streptococci vs. Intrapartum Antibiotic Prophylaxis in Peripartum Pregnant Women and their Neonates: A Review |
title_full_unstemmed | Immunization Against Group B Streptococci vs. Intrapartum Antibiotic Prophylaxis in Peripartum Pregnant Women and their Neonates: A Review |
title_short | Immunization Against Group B Streptococci vs. Intrapartum Antibiotic Prophylaxis in Peripartum Pregnant Women and their Neonates: A Review |
title_sort | immunization against group b streptococci vs. intrapartum antibiotic prophylaxis in peripartum pregnant women and their neonates: a review |
topic | Obstetrics/Gynecology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017184/ https://www.ncbi.nlm.nih.gov/pubmed/29946507 http://dx.doi.org/10.7759/cureus.1775 |
work_keys_str_mv | AT kristevamariya immunizationagainstgroupbstreptococcivsintrapartumantibioticprophylaxisinperipartumpregnantwomenandtheirneonatesareview AT tillmancatherine immunizationagainstgroupbstreptococcivsintrapartumantibioticprophylaxisinperipartumpregnantwomenandtheirneonatesareview AT goordeenashley immunizationagainstgroupbstreptococcivsintrapartumantibioticprophylaxisinperipartumpregnantwomenandtheirneonatesareview |